Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia

Phil Ok Koh, Clare M Bergson, Ashiwel S. Undie, Patricia S. Goldman-Rakic, Michael S. Lidow

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor-interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor-interacting protein calcyon and the D2 dopamine receptor-interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. Methods: Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. Results: The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. Conclusion: Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor-interacting proteins.

Original languageEnglish (US)
Pages (from-to)311-319
Number of pages9
JournalArchives of General Psychiatry
Volume60
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Receptor-Interacting Protein Serine-Threonine Kinases
Dopamine
Schizophrenia
Up-Regulation
Dopamine Receptors
Filamins
Prefrontal Cortex
Bipolar Disorder
Psychiatry
Proteins
calcyon
Protein
Depression
Research

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. / Koh, Phil Ok; Bergson, Clare M; Undie, Ashiwel S.; Goldman-Rakic, Patricia S.; Lidow, Michael S.

In: Archives of General Psychiatry, Vol. 60, No. 3, 01.03.2003, p. 311-319.

Research output: Contribution to journalArticle

Koh, Phil Ok ; Bergson, Clare M ; Undie, Ashiwel S. ; Goldman-Rakic, Patricia S. ; Lidow, Michael S. / Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. In: Archives of General Psychiatry. 2003 ; Vol. 60, No. 3. pp. 311-319.
@article{d5d81e35b09640adb72e39583b26d1a4,
title = "Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia",
abstract = "Background: The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor-interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor-interacting protein calcyon and the D2 dopamine receptor-interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. Methods: Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. Results: The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. Conclusion: Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor-interacting proteins.",
author = "Koh, {Phil Ok} and Bergson, {Clare M} and Undie, {Ashiwel S.} and Goldman-Rakic, {Patricia S.} and Lidow, {Michael S.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1001/archpsyc.60.3.311",
language = "English (US)",
volume = "60",
pages = "311--319",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia

AU - Koh, Phil Ok

AU - Bergson, Clare M

AU - Undie, Ashiwel S.

AU - Goldman-Rakic, Patricia S.

AU - Lidow, Michael S.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Background: The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor-interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor-interacting protein calcyon and the D2 dopamine receptor-interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. Methods: Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. Results: The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. Conclusion: Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor-interacting proteins.

AB - Background: The dopamine hypothesis remains a prominent influence on research into the pathogenesis of schizophrenia, yet the presence of consistent schizophrenia-linked abnormalities in the presynaptic components of the dopamine system or in dopamine receptors still remains a matter of debate. The present study focuses on a recently recognized group of dopamine receptor-interacting proteins as possible novel sites of dysfunction in schizophrenia. Specifically, we examined whether the D1 dopamine receptor-interacting protein calcyon and the D2 dopamine receptor-interacting proteins filamin-A and spinophilin are affected in the dorsolateral prefrontal cortex of patients with schizophrenia. Methods: Slot blots of dorsolateral prefrontal cortical tissue were used to compare the levels of the 3 proteins of interest in control, schizophrenic, bipolar, and major depression groups (n = 15 per group). The nonschizophrenic psychiatric groups were included to determine the specificity of the detected abnormalities. Results: The dorsolateral prefrontal cortex in schizophrenic patients displayed nearly twice the normal levels of calcyon, whereas filamin-A and spinophilin levels were unaltered. Patients with bipolar disorder or major depression showed no changes in all 3 proteins examined. Conclusion: Our findings provide the first evidence that abnormalities in the dopamine system of patients with schizophrenia may lie in altered levels of dopamine receptor-interacting proteins.

UR - http://www.scopus.com/inward/record.url?scp=0037335880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037335880&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.60.3.311

DO - 10.1001/archpsyc.60.3.311

M3 - Article

C2 - 12622665

AN - SCOPUS:0037335880

VL - 60

SP - 311

EP - 319

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 3

ER -